pharma · Agitation · Agitation,Psychomotor · BTAI
BioXcel Therapeutics
BioXcel Therapeutics trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.
555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US HQ
2017 Founded
56 Employees
Public company Type
BTAI · NYSE Ticker
Company details
- Status
- Public
- HQ
- 555 Long Wharf Dr, 12th floor, New Haven, Connecticut 06511, US
- Founded
- 2017
- Employees
- 56
- Programs
- 17
- Drugs
- 9
- Patents
- 18
BioXcel Therapeutics clinical trials
Registry index of 20 ClinicalTrials.gov studies linked to BioXcel Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
BioXcel Therapeutics trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for BioXcel Therapeutics.
-
Sublingual film containing Igalmi — Approved
Clinical update -
Sublingual film containing Dexmedetomidine (BXCL501) — Phase 3
Clinical update -
Sublingual film containing dexmedetomidine (BXCL501) — Phase 3
Clinical update -
Sublingual film containing Dexmedetomidine — Phase 2
Clinical update -
Sublingual film containing BXCL501 (Dexmedetomidine) — Phase 1
Clinical update -
Dexmedetomidine — Approved
Clinical update -
Dexmedetomidine — Phase 2
Clinical update -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg — Phase 1
Clinical update
Trial registry
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT04276883CT.gov ↗
Sublingual film containing Dexmedetomidine (BXCL501)
Agitation Associated With Bipolar Disorder
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT06335407CT.gov ↗
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Alcohol Use Disorder (AUD)
-
CT.gov ↗